Lauren Walzer, DO

Sonali D. Talsania, MD is an Assistant Professor of Ophthalmology at Columbia University Medical Center and the NewYork-Presbyterian Morgan Stanley Children’s Hospital. She is a board-certified ophthalmologist who completed fellowship training in pediatric ophthalmology and strabismus. She specializes in the ophthalmologic care of children and the surgical treatment of strabismus (eye misalignment) in both children and adults. She conducts general pediatric ophthalmologic exams and provides surgical and medical care for a variety of pediatric ophthalmologic conditions, including blocked tear ducts, amblyopia, childhood cataracts, dermoid cyst removal, and eyelid droop repair. She graduated summa cum laude from Harvard College with a degree in Biology (focus: Neurobiology) and was elected to the Phi Beta Kappa Society. She received her medical degree from Harvard Medical School and completed an internship at Cambridge Health Alliance, a Harvard training hospital. She then did her residency at Boston Medical Center, affiliated with Boston University. During residency, she was recognized for her work teaching medical students and received an award for her research in orbital cellulitis in children. She completed a fellowship in pediatric ophthalmology and strabismus at the Duke Eye Center and practiced for several years in South Florida before joining Columbia.Dr. Talsania is a member of the American Academy of Ophthalmology, as well as the American Association for Pediatric Ophthalmology and Strabismus. She has published in the field of pediatric ophthalmology on the topics of strabismus following glaucoma drainage device implantation and pediatric corneal cross-linking for keratoconus. She was selected as the Jonas Scholar for her work in pediatric ophthalmology at Columbia. She focuses on providing thoughtful care to patients of all ages, and is also dedicated to teaching residents, for which she was honored with the John Wheeler Martin Memorial Teaching Award.

Lora Glass, MD, is Associate Professor of Ophthalmology at Columbia University Medical Center and an Attending Ophthalmologist at New York-Presbyterian Hospital. She is a board-certified ophthalmologist, and completed fellowship training in ophthalmic plastic surgery under the auspices of the American Society of Ophthalmic Plastic and Reconstructive Surgery. Dr. Glass has particular clinical expertise in disorders of the eyelids, eyebrows, tear production and drainage systems, and orbital tissues surrounding the eyes in both children and adults. She enjoys working with patients and families to individualize medical and surgical plans that address all functional and cosmetic concerns. Dr. Glass graduated Summa Cum Laude from Harvard College with an A.B. in the Comparative Study of Religion; she was a John Harvard and Harvard College Scholar, and was elected to the Phi Beta Kappa Honor Society. Her medical degree was awarded at the Icahn School of Medicine at Mount Sinai, where she pursued additional training in medical ethics, and was elected a member of the Alpha Omega Alpha Honor Society. She completed an internship at the Memorial Sloan-Kettering Cancer Center and served on the institutional Ethics Committee while there. She then served as a resident and Chief Resident in ophthalmology at Columbia University. She returned to Harvard to pursue a two-year fellowship in ophthalmic plastic and reconstructive surgery at the Massachusetts Eye and Ear Infirmary. She followed her fellowship with a full-time faculty appointment at the Edward S. Harkness Eye Institute at Columbia University. Dr. Glass is an active contributor to the field of ophthalmic plastic and reconstructive surgery. She has written over 80 articles and chapters, and is an active member of the oculoplastics community both nationally and abroad. She is known for her attention to detail, addressing the needs and concerns of every patient and family.

Brian Marr, MD heads the Ophthalmic Oncology Service at the Harkness Eye Institute. He has comprehensive experience in the diagnosis, treatment, and management of ocular tumors including intraocular tumor resection, laser, radiation, and chemotherapy procedures. He has helped devise thousands of complex treatments for tumors of the eye, eyelid, orbit, and conjunctiva for his adult, children, and infant patients. Currently, Dr. Marr is a collaborator on a Columbia University clinical trial for a first-of-its-kind, new class of drug treatment for uveal melanoma. Dr. Marr is a board-certified ophthalmologist whose work has centered around ophthalmic oncology since 2000. One of the very few ocular oncologists trained in all aspects of eye cancer, Dr. Marr's clinical experience in treating these diseases is among the most extensive in the United States. His interest and experience in ophthalmic oncology began during an eight-year tenure in the Ocular Oncology Service at the Wills Eye Hospital in Philadelphia. There, he gained extensive experience treating intraocular tumors, and tumors of the eyelid, orbit, and conjunctiva in children and adults. It was there that Dr. Marr developed and improved many surgical procedures used to cure cancers of the eye, successfully treated thousands of patients, and helped their families though their battle with eye cancer. Next, Dr. Marr moved on to Memorial Sloan Kettering Cancer Center, where he remain for nine years, starting in 2008. Dr. Marr has some of the greatest experience with intra-arterial chemotherapy for treating retinoblastoma in the country, if not the world, as well as all other forms of retinoblastoma treatment. He has been a key member of many multidisciplinary surgical teams, treating advanced skull base tumors and complex facial skin lesions. He has developed a strong belief and treatment philosophy that the best research be used to help his patients, rather than his best patients be used to help his research. The field of ophthalmic oncology encompasses many rare conditions and his experience helps his patients get the best care and results as quickly as possible. Dr. Marr lectures and consults across the US and abroad, and has authored numerous research articles in the field of ocular oncology. He is the principal investigator in a first-in-class drug study for treating primary uveal melanoma, in an international, multi-center trial. He also volunteers his medical expertise in underserviced parts of the world, such as Nigeria and Indonesia, and has helped train physicians in more than 20 countries. Dr. Marr’s efforts as a contributor to ongoing education in ocular oncology have been recognized by the American Academy of Ophthalmology, where he now serves as chief editor of the Academy’s Oncology and Pathology’s One network.